Goodwin Procter LLP advised Vaccitech on the deal, while Davis Polk advised the representatives of the several underwriters.Vaccitech (Nasdaq: VACC) announced its initial public offering in…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
